Irving, TX (PRWEB) May 14, 2013
Top companies are making strategic acquisitions to expand their global footprint, together with taking advantage of established business and expertise gained through the acquired company. The global generic drugs industry experienced average growth over the last five years and is expected to reach approximately US $335.8 billion in 2017.
Lucintel, a leading global management consulting and market research firm, has conducted a competitive analysis of the global generic drugs companies and presents its findings in “Top Five Global Generic Drug Companies Performance, Strategies, and Competitive Analysis.” The report provides detailed insight into the performance of the top five generic drug companies across the world. The analysis highlights the companies that are performing the best among the peer group, and in which areas, and therefore clarifies leading performance standards and the strengths and weaknesses of companies covered.
The fragmented generic drugs industry includes producers of medications whose patent or marketing rights have expired. The industry includes drugs from all therapeutic areas: central nervous system, cardiovascular drugs, oncology drugs, and others. A combination of factors such as technology innovations, patent expiration, aging population, and changing lifestyles substantially affect market dynamics. In this study, Lucintel profiles the following five companies with detailed competitive assessments:
- Abbott Laboratories
- Mylan Inc.
- Novartis AG
- Teva Pharmaceuticals Ind. Ltd.
- Watson Pharmaceuticals Inc
As indicated in Lucintel’s study, the Asia Pacific (APAC) region holds good growth potential. India is expected to play an increasing role in the global economy as demand from a growing population continues to drive consumption for generic drugs. Major pharmaceuticals companies are planning to invest in the Asian markets to gain the market share for generic drugs.
This medical market report provides industry leaders with a competitive benchmarking of the world’s top five generic drug companies. The study provides up-to-date information on the market share, profit margins, capabilities, and business strategies of the leaders. It is designed to provide executives with strategically significant competitor information, data analysis, and insight, critical to the development and implementation of effective marketing and sales plans.
For a detailed table of contents and pricing information on this timely, insightful report, contact Lucintel at +1-972-636-5056 or via email at helpdesk(at)lucintel(dot)com. Lucintel provides cutting-edge decision support services that facilitate critical decisions with greater speed, insight, M & A due diligence and cost efficiency. To learn more, visit http://www.lucintel.com